Michael Barbella, Managing Editor10.09.23
Vitrolife AB has appointed Jón Sigurdsson as board chairman, succeeding Henrik Blomquist, who stepped down from the position. The company did not provide a reason for Blomquist's decision.
Board member Vesa Koskinen, appointed by EQT VIII, has also resigned from the board (at his own request). He has been with the governing body since Dec. 1, 2021. “On behalf of the board, I would like to thank Vesa Koskinen for his contributions during his time as a board member,” Sigurdsson said.
Vitrolife's board now consists of Sigurdsson, Blomquist, Karen Lykke Sørensen, Lars Holmqvist, and Pia Marions. Blomquist replaces Koskinen on the Audit Committee.
The Vitrolife Group is a global provider of medical devices and genetic testing services. Dedicated to the reproductive-health market since 1994, the company has grown by focusing on product development, research, quality control, and acquisitions of innovative companies in the industry. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarily for IVF clinics. The Vitrolife Group consists of approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Its products and services are available in more than 125 countries, through its own presence in more than 25 countries and a vast network of global distributors.
Board member Vesa Koskinen, appointed by EQT VIII, has also resigned from the board (at his own request). He has been with the governing body since Dec. 1, 2021. “On behalf of the board, I would like to thank Vesa Koskinen for his contributions during his time as a board member,” Sigurdsson said.
Vitrolife's board now consists of Sigurdsson, Blomquist, Karen Lykke Sørensen, Lars Holmqvist, and Pia Marions. Blomquist replaces Koskinen on the Audit Committee.
The Vitrolife Group is a global provider of medical devices and genetic testing services. Dedicated to the reproductive-health market since 1994, the company has grown by focusing on product development, research, quality control, and acquisitions of innovative companies in the industry. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarily for IVF clinics. The Vitrolife Group consists of approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Its products and services are available in more than 125 countries, through its own presence in more than 25 countries and a vast network of global distributors.